Authorization

Research Suggests Some Premature Infants May Go Home From the NICU Up To Three Weeks Earlier When Fed Prolactaa??s 100% Human Milk-Based Nutritional Products; Those with Bronchopulmonary Dysplasia...

DUARTE, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- A retrospective study indicates that premature infantsa?? stays in neonatal intensive care units (NICUs) are reduced anywhere from 4.5 to 22.9 days when fed Prolacta BioscienceA® 100% human milk-based products as a part of an Exclusive Human Milk Diet (EHMD)1. Additional research suggests that infants with bronchopulmonary dysplasia (BPD), a common complication of prematurity, may benefit the most from an EHMD when it comes to shortening their hospital stays.


A retrospective study published in the Journal of Perinatology found that 293 infants between gestational ages 23 and 34 weeks and birth weights between 490 and 1,700 g who received Prolactaa??s fortifiers as part of an EHMD achieved full feeds at faster rates and ultimately reduced their NICU stay by 4.5 to 22.9 days, compared with infants fed their mothera??s milk with a cow milk-based fortifier or a combination of moma??s milk with cow milk-based fortifier and formula.2



Frontiers in Pediatrics published findings from a study of more than 12,000 premature infants born at a?¤ 28 weeks indicating that among the 41% who developed BPD, hospital stays were 19 days longer on average (P = .001) than those who did not develop BPD.3



A secondary analysis of a study that originally looked at the impact of Prolactaa??s cream fortifier on growth among premature infants weighing 750 to 1,250a??g showed that adding Prolactaa??s human milk-based cream fortifier to an EHMD resulted in an average stay in the NICU that was 12 days shorter, from 86 days without the cream supplement to 74 days when it was used. In this study, the infants with BPD may have benefited the most from the addition of Prolactaa??s cream fortifier, with 17 fewer days in the NICU, from an average of 121 to 104 days (P = .08). This updated analysis was published in Breastfeeding Medicine in 2016.4



A 2019 study published in Advances in Neonatal Care compared 104 infants born weighing
a?¤ 1,250 g who received an EHMD to a similar group of 101 infants who received cow milk-based fortifier. In this study, an EHMD was associated with decreased rates of BPD (P = .018) and sepsis (P = .06) and an average five-day reduction in length of hospital stay.5

a??The goal of all parents with a premature infant in the NICU is to bring their baby home as soon as possible. When you add the concerns about exposure to hospital-based infections for both the parents and the baby, that desire for discharge is stronger than ever,a?? said Melinda Elliott, M.D., chief medical officer of Prolacta. a??The clinical evidence shows an EHMD including Prolactaa??s products helps to overcome the complications of prematurity, resulting in better health outcomes and shorter hospital stays in the NICU.a??
About Prolacta Bioscience
Prolacta BioscienceA®A Inc. is a privately held life sciences company dedicated to Advancing the Science of Human MilkA®. Prolacta is the worlda??s leading hospital provider of 100% human milk-based nutritional products. These life-saving products have reduced complications and improved the health of more than 63,000 extremely premature infants globally. In addition, the company is exploring the therapeutic potential of human milk across a wide spectrum of human diseases, including applications for infants requiring surgery for congenital cardiac and gastrointestinal disorders. Operating the worlda??s first pharmaceutical-grade human milk processing facilities, Prolacta leads the industry with the highest quality and safety standards for the screening and testing of donor milk. Prolacta is a global company with headquarters in Duarte, California, andA can be found online atA www.prolacta.com, on TwitterA @prolacta, on InstagramA @prolacta_bioscience, on Facebook atA www.facebook.com/prolactaA and LinkedIn atA www.linkedin.com/company/prolacta-bioscience/.www.prolacta.comMedia Contact:
Loren Kosmont
Lkosmont@prolacta.com
310-721-9444
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Сентябрь 2020    »
ПнВтСрЧтПтСбВс
 123456
78910111213
14151617181920
21222324252627
282930